Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Has anyone got a copy of McGladrey's letter? They were not attached to what I saw online at:
http://biz.yahoo.com/e/131217/cdxc8-k.html
"17-Dec-2013
Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
Item 4.01 Change in Registrant's Certifying Accountant
On December 11, 2013, the Audit Committee of the Board of Directors (the "Board") of Chromadex Corporation (the "Company") approved the dismissal of McGladrey LLP ("McGladrey") as the Company's independent registered public accounting firm.
During the fiscal years ended December 29, 2012 and December 31, 2011, McGladrey's reports on the Company's financial statements did not contain an adverse opinion or disclaimer of opinion, and were not qualified or modified as to uncertainty, audit scope or accounting principles, except to the extent disclosed in the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on November 21, 2013.
During the fiscal years ended December 29, 2012 and December 31, 2011 and the subsequent periods through December 11, 2013, (i) there were no disagreements between the Company and McGladrey on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of McGladrey, would have caused McGladrey to make reference to the subject matter of the disagreements in connection with its reports on the Company's financial statements; and (ii) there were no reportable events as that term is described in Item 304(a)(1)(v) of Regulation S-K, except (i) to the extent disclosed in the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on November 21, 2013, (ii) McGladrey's letter to the Audit Committee of the Board, dated November 21, 2013, in which McGladrey identified a material weakness in the Company's internal control over financial reporting, and (iii) McGladrey's audit report for the year ended December 31, 2011 stated that, in McGladrey's opinion, the Company and its subsidiaries had not maintained effective internal control over financial reporting as of December 31, 2011.
On December 11, 2013, the Company provided McGladrey with a copy of the disclosures it is making in response to Item 4.01 on this Form 8-K, and requested that McGladrey furnish it with a letter addressed to the Securities and Exchange Commission stating whether it agrees with the above statements. A copy of the letter, dated December 17, 2013, is filed as Exhibit 16.1 (which is incorporated by reference herein) to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits.
The exhibits listed in the following Exhibit Index are filed as part of this Current Report on Form 8-K.
Exhibit No . Description
16.1 Letter from McGladrey LLP dated December 17, 2013 "
Phillip Frost now wrapping up and citing many other products under developemnt. Now the questions....
At least on my replay, Steve Rubin is now speaking about the potential from the drug programs acquired via Prolor, which Lakewood had essentially ignored.
You should download the slide deck. Which I found at:
http://files.shareholder.com/downloads/OPKO/2847397040x0x714136/ea951ad4-1e96-44a4-ad63-4741d3960ff1/OPKO%20Conf%20Call%2012-17-13%20v%2010.pdf
It was mentioned last week. It is recorded, at the link: http://investor.opko.com/events.cfm
Just register and you can see the slide deck and listen to the presentation ... which does appear to be a reiteration of past stuff and of their strong pipeline and not a refutation of Lakewood, at least as far as I've listened.
EDIT: and a further haircut seems to be in process, down $.75.
Edit: In a sense it is a refutation, but showing what IS underway and the timelines.
Really good volume today, almost 94k shares. Lots of price volatility, ending waaay up. EOM.
Form 10-Q for BEESFREE, INC.
14-Nov-2013
Quarterly Report http://biz.yahoo.com/e/131114/bees10-q.html
Note 2 - Going Concern and Management Liquidity Plans
The Company is currently in the development stage, has not yet generated any revenues, and has incurred net losses since inception. As of September 30, 2013, the Company had cash of approximately $84,000 and a working capital deficiency of approximately $1,491,000. The Company believes that its current cash on hand will only be sufficient to fund its projecting operating requirements to the end of November 2013. These conditions raise substantial doubt about the Company's ability to continue as a going concern.
The Company's primary source of operating funds since inception has been cash proceeds from the sale of convertible debentures and the sale of preferred stock and warrants in private placements. The Company intends to raise additional capital through private debt and equity investors, but there can be no assurance that these funds will be available on terms acceptable to the Company, or will be sufficient to enable the Company to fully complete its development activities or sustain operations. If the Company is unable to raise sufficient additional funds, it will have to develop and implement a plan to further extend payables, reduce overhead, or scale back its current business plan until sufficient additional capital is raised to support further operations. There can be no assurance that such a plan will be successful.
Accordingly, the accompanying condensed consolidated financial statements have been prepared in conformity with U.S. GAAP, which contemplates continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values. The condensed consolidated financial statements do not include any adjustment that might result from the outcome of this uncertainty.
Hmmm. What happened today? .007 per share?
That comports with all the zeros for trades in all my otc stocks.
MMom,
If I were the holder of the convertible note, which I am not, I would wait until nearly the last minute to exercise my conversion right at $.05. There is no penalty to wait, as long as the price doesn't go to $.15 yet, and the holder has the added security of remaining a creditor, should some unforeseen negative event take place. Note I am NOT predicting a negative event, but as an angel investor (not such in BCYP), I've learned to keep my options open. I am long over 100k shares, so I do keep an eye on this. I am optimistic and plan on holding until either a buyout or a very nice pop after other settlements or the Markman.
Steve
I received an invitation for the call and think a couple more technical types like BK and SEEL, etc, could get in.
And the information for that call is:
Friday 11.1.13 at 2:00 PM ET(11:00 AM PT)
Dial-In 888-428-7458
Webcast info: www.infiniteconferencing.com/join
Code: 13274022
Conference Call Replay: (888) 539-4649 or
(908) 379-8864
replay code (97747#)
Please RSVP to Jared Mitchell at jmitchell@proactivecrg.com
Medical Expert:
Stephen Sonis DMD, DMSc Clinical Professor of Oral Medicine at Harvard School of Dental Medicine, Senior Surgeon and Chief, Divisions of Oral Medicine at Brigham and Women's Hospital and the Dana-Farber Cancer Institute, and Scientific Advisory Board Member and Lead Advisor for Soligenix.
Soligenix Participants
Christopher J. Schaber PhD, President & Chief Executive Officer
Oreola Donini, PhD, Vice President of Preclinical Research & Development
Analyst Moderator(s)
Maxim Group’s Biotechnology Team: Jason Kolbert; Echo He, MD PhD; and Shaukat Khan, PhD
Discussion Topics
What is Oral Mucositis?
Oral mucositis is a debilitating side effect of cancer treatments. Depending on the severity of oral mucositis, patients may be unable to swallow, eat or speak. Oral mucositis is thought to be exacerbated by the innate immune response to the damage caused by radiation and/or chemotherapy treatment of cancer.
What is the need?
Oral mucositis still represents an unmet medical need. The current treatments include basic oral care, cryotherapy, topical rinses such as lidocaine, MuGard™, and Kepivance® (palifermin), a growth factor for use with hematological malignancies only. None of the above therapies have been completely successful in treating mucositis, particularly in patients with solid tumors (HNC, breast, colon etc.), and a high unmet medical need exists.
What is Soligenix developing?
Soligenix is developing a “novel innate defense regulator (IDR)”, SGX942, for the treatment of oral mucositis caused by chemoradiation therapy in HNC patients.
Well, well well. Broke $12.
EDVA Comment on his blog:
http://edvapatent.wordpress.com/2013/10/10/blue-calypso-bcyp-partners-with-integracolor-launches-blue-calypso-labs/#comments
edvapatent October 14, 2013 at 1:37 pm #
Pipe. We all would have liked the .13 deal, no doubt, but then again we are not Bernay Box. He is listed as a “strategic” investor for a reason. His ability to introduce top tier clients (see Chairman of Points Internation Ltd. and what their client list looks like) to BCYP, which we assume is already underway, should not be taken lightly. BCYP didn’t just give up .13 in some knuckle-headed deal I assure you. They clearly expect something from Mr. Box. Mr. Box is also locked up on the sale of his shares for six months which should tell you, and other investors, something about what he thinks of BCYP. I’m sure I don’t need to point out that that period extends well beyond the Markman hearing and so Mr. Box is either a riverboat gambler or he has reason to believe (and I am sure he has had his own team do extensive research) that BCYP is going places and that their patents are valid and being infringed upon. I said in a post about a week ago that I expected we would see more 13-d’s being filed soon and I expect more still. We may see some where the share price is in keeping with what BCYP expects to get from that specific investor beyond cash (again strategic investor), others may be at market. To be quite honest at this point we don’t really care if they continue to add these kind of people. These guys are not short-termers (Ron Chez is included here) and simply do not need to fool with companies that they think are less than promising. As for comments about other authors who speculate based upon solid information, just as we do, we would say only that we don’t often see such people making guarantees. Natty Greene’s article on Groupon was a pretty solid effort and we actually think BCYP is an Achilles heel for GRPN. Whether that means they will settle now or wait until the Markman result to decide what to do there is no way to know. That said, there is ample reason for them to settle just as there is for the other defendants. We do not follow the writings of authors concerning stocks outside of the patent space so as to his or anyone else’s writings outside of this space we would not presume to weigh in on that. As always, thanks for your comments."
It was Barry Honig, per openinsider:
http://openinsider.com/search?q=pglc
According to the Daily Summary of insider purchases at J3SG
someone today filed that they purchased 117,500 shares of PGLC at $0.37.
Steve
I'm flattered that you ask me, but I'm totally unable to answer. Perhaps TallDude or Tommy have an opinion?
Interesting item on al jazeera america on bee colony collapse. While I posted the text, you'll have to go to the site to see images.
http://america.aljazeera.com/watch/shows/techknow/blog/2013/9/29/u-s-scientists-worktosavethebeepopulationandamericasfood.html
Sep 29
U.S. scientists work to save the bee population and America’s food
by Meredith Kile
On this week’s “TechKnow,” contributor and science writer Kyle Hill travels to Minnesota and Washington to explore the phenomenon known as “colony collapse” and the devastating effects that the loss of honey bees could have on the American food industry.
Ellis shows Kyle his farm.
Steve Ellis introduces Kyle to his bee farm.
“The losses are really astronomical,” says Steve Ellis, a beekeeper from Barrett, Minn. “Last winter I lost 65 percent of my operation.”
Ellis is one of many beekeepers who has made his living in the commercial bee industry, raising colonies for honey as well as to rent out to commercial food growers to help pollinate their crops. He is also one of many beekeepers who have begun to see large-scale deaths and disappearances among his bee population.
The effect of colony collapse.
Honey bees are incredibly important to the U.S. food supply, of which about one-third relies on bees for pollination. They also provide over $15 billion in revenue for the agriculture industry.
“The demand for insect-pollinated crops—the nuts, the fruits, the vegetable— is very much increasing,” Ellis tells Hill. “The supply of bees is very much decreasing.”
The term scientists use to explain the massive bee deaths and disappearances that are starting to become common across the country is “colony collapse disorder.” Colony collapse has been observed before, but beekeepers claim that it was nothing like the mass disappearances and deaths that they are now seeing in their colonies.
As our colleagues at Al Jazeera America have reported, a pesticide class known as nenicotinoids may account for some of the deaths, though diseases and parasites could also impact bees’ feeding and health.
For this reason, scientists have focused instead on creating a better bee, using artificial insemination to genetically engineer a stronger, healthier bee that can fight off colony collapse.
Susan Cobey in her bee insemination lab.
Susan Cobey in the lab where she conducts queen bee inseminations.Al Jazeera America
Susan Cobey works with a team of researchers from Washington State University who are using genetic engineering to try and create better bees. After years spent studying bees, she knows first-hand how hard it is to pinpoint and stave off the causes of colony collapse.
“There’s lots of different aspects to it,” Cobey says. “You have to look at the environment, exposure to pesticides, malnutrition due to lack of forage for the bees, pests, parasites, and pathogens.”
At her organic farm on Whidbey Island in Washington’s Puget Sound, Cobey raises drone bees that can survive harsh hive conditions. She extracts semen from the drones and fertilizes queen bees in the hopes that the resulting offspring share an enhanced combination of their resilient parent DNA.
“With instrumental insemination, I can do things that don’t happen in nature,” Cobey explains. “I’m trying to enhance what Mother Nature does.”
What does a rig for inseminating a queen bee look like? Rather surgical @ajam @AJTechKnow pic.twitter.com/LvDnYjzDRm
— Kyle Hill (@Sci_Phile) August 29, 2013
“The more drones [the queen] mates with, the more diversity and the better fitness you have,” Cobey tells Hill. “The goal now is to have gentle, productive bees, but now I also want bees that are resistant to all these pests and problems we have, which is a tall order. I will spend probably the rest of my life trying to do that.”
At the Smoot Hill Reserve in Pullman, Washington, more Washington State researchers are collecting and breeding honey bee samples from around the world. By pioneering technology that allowed them to cryogenically freeze honey bee sperm samples, the scientists are able to catalogue samples spanning the distance of the globe as well as a few decades. They have essentially created the world’s first bee sperm bank.
Bee semen being cryogenically frozen for storage.
“Before we developed this technique, it basically didn’t work,” scientist and Washington State student Brandon Hopkins explains to Hill. “Nobody in the world was able to freeze honey bee semen. It’s a very extreme environment for these cells to be put through. If it’s not done just right, it’s going to be useless.”
After the semen is safely frozen, it can be stored for years or utilized at Smoot Hill in what entomologist Walter Sheppard describes to Hill as “isolated mating stations,” individualized colonies that allow researchers to control the mating and specify the genetics that combine to form each new generation.
Sheppard and Kyle.
Kyle observes a bee mating unit up close.Al Jazeera America
“We can put colonies here that have the particulars males that we want for the mating,” Sheppard tells Hill. “We have virgin queens here that have been produced from crosses that we’ve made using the frozen semen.”
A queen bee is carefully inseminated with drone bee semen.
Cobey, Sheppard, and their fellow researchers are working to increase the health of bee populations before colony collapse takes it’s toll on the American food industry. Beekeepers like Ellis are certainly already aware of the potentially dire consequences of continued honey bee loss.
“We have reached a disaster point, from a beekeeping industry standpoint,” Ellis concludes. “It just needs to be understood by the people of the country that we have a Deepwater Horizon occurring with pollinators and we need to deal with it.”
And the following link brings up Honig's insider trades in all stocks:
http://www.insidercow.com/history/insider.jsp?Cik=0001373203&company=PGLC&name=Honig%20Barry%20C&title=%20director%2010%%20owner
You can sort it by clicking on "company" column heading. CDXC comes up, in addition to the non-medical companies.
Steve
Purely IMHO, Frost probably got them below market when PGLC desperately needed cash. Honig can smell the money coming when this either starts producing or is acquired.
BTW, you can see more detail on the trades, including form 4s, at: http://www.insidercow.com/history/company.jsp?company=pglc&B1=Search!
but the large purchase was not picked up here, unless I'm going blind.
Steve
ds,
If you go here: http://www.nasdaq.com/symbol/pglc/insider-trades
you will see that Frost sold a few shares in june (187,000) a couple months after buying 6+ million. He did sell some in 2012 as well. After the sales, he still held over 53 million shares, which is more than he held in 2012.
Steve
Planning on holding the OPK stock anyway for a long time. Long live PBTH.
And I just got most of our forms today, each six pages long, plus an instruction booklet. I say forms because I had PBTH in five accounts. I guess it'll get easier after the first one. Have fun with yours too.
Wild, As noted as footnotes to the form 4, and for the benefit of those who do not actually read the Form 4s, the disposal was in connection with the merger into OPK, as these options were replaced with options on OPK:
"Explanation of Responses:
( 1 )Disposed of pursuant to an Agreement and Plan of Merger, dated as of April 23, 2013 (the "Merger Agreement"), by and among the Issuer, OPKO Health, Inc. ("OPKO") and POM Acquisition, Inc. ("POM"), a wholly-owned subsidiary of OPKO formed for the purpose of facilitating the merger of POM with and into the Issuer (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.00001 per share, of the Issuer was cancelled and converted into the right to receive 0.9951 of a share of common stock, par value $0.01 per share, of OPKO ("OPKO Common Stock"). The OPKO Common Stock has a market value of $8.49 per share (based on the closing price per share of OPKO Common Stock on August 29, 2013, the effective date of the Merger).
( 2 )These securities are held by Frost Gamma Investments Trust, of which the Reporting Person is the trustee. Frost Gamma Limited Partnership is the sole and exclusive beneficiary of Frost Gamma Investments Trust. The Reporting Person is one of two limited partners of Frost Gamma Limited Partnership. The general partner of Frost Gamma Limited Partnership is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation, of which the Reporting Person is the sole shareholder.
( 3 )Pursuant to the Merger Agreement, this option, which vested in 1 installment on February 5, 2010, was assumed by OPKO at the effective time of the Merger and replaced with an option to purchase 24,877 shares of OPKO Common Stock at an exercise price of $0.66 per share.
( 4 )Pursuant to the Merger Agreement, this option, which vested in 1 installment on August 4, 2012, was assumed by OPKO at the effective time of the Merger and replaced with an option to purchase 54,730 shares of OPKO Common Stock at an exercise price of $5.50 per share.
( 5 )Pursuant to the Merger Agreement, this option, which provided for vesting in 12 equal monthly installments beginning on March 4, 2013, was assumed by OPKO at the effective time of the Merger and replaced with an option to purchase 539,344 shares of OPKO Common Stock at an exercise price of $4.77 per share. In addition, pursuant to the stock option agreement governing this option, at the effective time of the Merger this option became fully vested and exercisable."
DS, According to my broker (Fidelity) the forms were to be sent out last week. Have seen nothing yet. May have to repeat call.
Big Initial Sale to Argentina.
http://www.sacbee.com/2013/09/16/5740029/beesfree-receives-large-initial.html
"BeesFree Receives Large Initial Sales Order of BeesVita Plus™ from Major Distributor of Bee Products in Argentina
By BeesFree, Inc.
Published: Monday, Sep. 16, 2013 - 6:07 am
WEST PALM BEACH, Fla., Sept. 16, 2013 -- /PRNewswire/ -- BeesFree, Inc. (OTC QB:BEES), the worldwide distributor of BeesVita Plus™, announced that it has received an order of approximately $300,000USD from a major distributor of products to many of the largest beekeepers in Argentina. The order was generated as a result of the recently announced collaboration with Oleogram SA, an Argentine company recognized as an expert in new product and technology development in the agricultural sector.
(Logo: http://photos.prnewswire.com/prnh/20130731/FL56383LOGO)
"Everyone at Oleogram is really excited about the many positive responses we have received from beekeepers country-wide. We have no doubts at all about the future success of BeesVita Plus™ that we are projecting for the Argentine market," commented Mr. Jose Maria Sammartino, President and Carlos Colombini, Vice President of Oleogram SA.
This initial purchase order comes right on the heels of the recently announced manufacturing agreement to supply the United States market with BeesVita Plus™. The purchase is a result of a strong positive reaction that BeesFree has received from beekeepers in Argentina that have observed the preliminary test results and tried the product as a treatment for the devastating effects of Colony Collapse Disorder which has been killing millions of essential honeybees for the past few years.
Mr. Daniel de Elizade, a major honey trader-reseller and beekeepers provider in the region stated "I have chosen to order the product after my long experience in the industry. I am convinced that to face the dramatic situation that honeybees are dealing with including lack of nectar, climate disruption and use and abuse of a new generation of deadly pesticides for massive crops, we must radically change how we are facing the problem. BeesVita Plus™ is something new and effective that simultaneously increases the honeybee population and enhances the beekeeper's productivity".
Colony Collapse Disorder is the mass disappearance of honey bee colonies. Honeybees are important pollinators for both flowers and agricultural crops. Without bees to pollinate many popular fruit and vegetables, the United States alone could lose $15 billion worth of crops. Nearly one-third of all honeybee colonies in the country have vanished, never to return. The latest data, from the 2012-2013 winter, indicate an average loss of 45.1 percent of hives across all U.S. beekeepers, up 78.2 percent from the previous winter, and a total loss of 31.1 percent of commercial hives, on par with the last six years.
Joseph Fasciglione, Interim Chief Executive Officer of BeesFree, Inc., commented, "The receipt of this initial purchase order is from one of the more influential exporters and resellers of honeybee food products to large beekeepers throughout Argentina and internationally. Based on our conversations with the purchaser, we look forward to the opportunity to potentially supply this company with a continuous supply of BeesVita Plus™ over the next few months."
About BeesFree, Inc.
BeesFree, Inc. (OTC QB:BEES), a company focused on developing innovative solutions for the global beekeeping community, owns a patent-pending composite food solution that helps honeybees avoid the effects of Colony Collapse Disorder (CCD). Visit www.beesfree.biz to learn more about why the bees are disappearing, and how beekeepers can combat the honeybee decline.
Forward-Looking Statement
Statements about the future expectations of BeesFree, Inc. and all other statements in this press release other than historical facts, are "forwarding-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as that term is defined in the Private Securities Litigation Reform Act of 1995. BeesFree, Inc. intends that such forward-looking statements shall be subject to the safe harbors created thereby. Since these statements involve certain risks and uncertainties and are subject to change at any time, BeesFree's actual results could differ materially from expected results.
Contact: Joseph N. Fasciglione Interim Chief Executive Officer 561.939.4860 j.fasciglione@beesfree.biz"
NJ,
So, do you see them becoming a NPE? Do you foresee them just licensing the IP they have, co-oping with an entity like MARA by assigning them the IP, or taking the MARA route themselves?
Steve
Investor,
Yes, The growing web of companies in which Dr. Frost has invested are very impressive - and all are speculative.
Steve
And OPK hit a high of over $9.40. Somehow, I suspect that almost all PBTH holders are now happy to have been acquired by OPK.
BTW, I do not expect this trajectory to continue without pullback and consolidation. All just IMHO.
Good luck to all new longs in OPK. We'll see how soon this page is shut down.
Well, quite the volatility today. 12.4 cents to 51 cents.
The article on Dr. Frost is somewhat lacking in substance but thank you for pointing it out. It is interesting to see where he is heading and I had not yet noticed it.
Dr. Frost's investments include OPK and PBTH and those others we mentioned before. Also Ladenburg Thalmann (LTS) which I believe is the company to which you referred. I think he owns a major portion of that as well He is listed as at least a 10% owner on the link below). NIMU and SFES were too thinly traded for me to get in when I looked. Some of the entities like LTS and PGLC clearly don't fit in the health sciences mold and must have just presented good investment opportunities for his portfolio.
Interestingly, he has made no purchases at all since 7/25 in OPK. Given the strength in that stock, underpinning PBTH, it appears to have transitioned from mostly being driven by his purchases to recently building organically.
In case you don't have the tool, I use:
http://openinsider.com/insider/Frost-Phillip-Md-Et-Al/898860
I got it as well. Seems to just require NBS to adhere to better corporate governance practices and give the attorneys a fee. I saw no payment to persons/entities who were shareholders as of August 24, 2012 and no action required. It does not affect holders who sold before that date or who purchased it after. Please correct me if I read it wrong.
Hi John,
Yeah, I guess we are not the only "Frost groupies." I have PBTH, OPK, PGLC, ROX and CDXC among his investments. Somehow I never did SafeStitch or MusclePharm. Lets hope these are all winners, with a focus on PBTH and OPK for now.
Steve
It is virtually certain that the merger/acquisition will take place. All the legal investigations are basically "ambulance-chasing" attorneys (with apologies to one cousin who was an ambulance chaser) looking to score lead position in a class-action suit which they hope will turn up some misdeed, like the BOD not performing their fiduciary duty to shareholders. Usually, absent a smoking gun or clear self-dealing, it is hard to win such cases. Often, cases are filed simply in hopes of scoring a nuisance settlement from the company being sued, with the attorneys taking at least one-third of that. They are easy to file and these guys have the templates all ready.
If you do a google search on the names of the law firms soliciting PBTH shareholders as clients, you will see they have filed many, many similar suits on virtually every merger/acquisition.
While I personally felt that PBTH had a ladder of success ahead of it as an independent entity, I also own some OPK shares and am mollified by the higher price.
All of the foregoing is just IMHO, and does not constitute investment advice.
Thank you.
Maybe I missed it but has NBS management directly addressed the studies which disputed the validity of their technology? I saw personnel appointments, but not a defense of their system.
Hi NJ,
Long time no talk. Just thought I'd post the news below and ask for your take on what this portends for TSRA and your current assessment of TSRA.
Steve
"Tessera Technologies Sells Micro-Optics Assets to FLIR
by Business Wire via The Motley Fool Aug 12th 2013 7:39AM
Updated Aug 12th 2013 7:44AM
Tessera Technologies Sells Micro-Optics Assets to FLIR
SAN JOSE, Calif.--(BUSINESS WIRE)-- Tessera Technologies, Inc. (NAS: TSRA) (the "Company" or "Tessera") announced today that FLIR Systems, Inc. ("FLIR") has acquired a significant portion of the assets of Tessera's Micro-Optics business based in Charlotte, North Carolina. Total consideration paid by FLIR was approximately $15 million.
"This transaction is one of the substantive structural changes we announced we would make in the second half of 2013 as we continue to refine our focus on our differentiated MEMS-related technologies," stated Thomas Lacey, interim CEO of Tessera Technologies, Inc. "I would like to thank the Micro-Optics employees for their contributions and efforts and believe this transaction is the right step forward for the future of that business."
Discontinued Operations
In the fourth quarter of 2012, the Company announced that its Micro-Optics business in Charlotte, North Carolina was no longer part of its long-term strategy, and that it was exploring strategic alternatives for this business. In the second quarter of 2013, the Company actively pursued a sale of this business and started classifying the business as discontinued operations."
I think it is a wise move to buy as long as the spread between PBTH and OPK is large enough. It was 61 cents at the close, which puts it at about 8-9 percent. I have some of both companies shares, but am much more heavily into PBTH, basically at the limit I put into a single stock.